title: "Paradoxical" arthralgia occurring under anti-TNFα treatment for inflammatory bowel disease.
authors.affiliation: Department of Rheumatology, University Teaching Hospital, CHRU, 25030 Besançon, France.
authors.forename: Maxime
authors.initials: M
authors.lastname: Sondag
authors.affiliation: Department of Rheumatology, University Teaching Hospital, CHRU, 25030 Besançon, France.
authors.forename: Frank
authors.initials: F
authors.lastname: Verhoeven
authors.affiliation: Department of Rheumatology, University Teaching Hospital, CHRU, 25030 Besançon, France.
authors.forename: Xavier
authors.initials: X
authors.lastname: Guillot
authors.affiliation: Department of Rheumatology, University Teaching Hospital, CHRU, 25030 Besançon, France.
authors.forename: Clément
authors.initials: C
authors.lastname: Prati
authors.affiliation: Department of Gastro-enterology, University Teaching Hospital, CHRU, 25030 Besançon, France.
authors.forename: Charline
authors.initials: C
authors.lastname: Briot
authors.affiliation: Department of Gastro-enterology, University Teaching Hospital, CHRU, 25030 Besançon, France.
authors.forename: Lucine
authors.initials: L
authors.lastname: Vuitton
authors.affiliation: Department of Gastro-enterology, University Teaching Hospital, CHRU, 25030 Besançon, France.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Koch
authors.affiliation: Department of Rheumatology, University Teaching Hospital, CHRU, 25030 Besançon, France. Electronic address: dwendling@chu-besancon.fr.
authors.forename: Daniel
authors.initials: D
authors.lastname: Wendling
mesh_terms: D000068879:Adalimumab / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D018771:Arthralgia / Q000139:chemically induced* / Q000175:diagnosis; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; C529000:golimumab; D000069285:Infliximab; D000068879:Adalimumab
keywords: Inflammatory bowel disease; Infliximab trough level; Methotrexate; Paradoxical arthralgia; Spondyloarthritis; TNF blockers